Daratumumab (Darzalex)

Daratumumab (Darzalex) is a monoclonal antibody immunotherapy used to treat newly diagnosed and relapsed/refractory multiple myeloma, often in combination with other therapies. It targets the CD38 protein on myeloma cells, killing them through immune-mediated mechanisms. Common side effects include infusion-related reactions, fatigue, nausea, diarrhea, and upper respiratory infections.